Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials
#4PRI RANKED
Most Cited Paper
in Heart Failure Treatment and Management
18 Months Post-Publication
Class of 2026
“Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/heart-failure-treatment-and-management/2026/
Topics
Semaglutide · Obesity-related HFpEF · Heart failure with preserved ejection fraction · STEP-HFpEF trial · STEP-HFpEF DM trial · Pooled analysis · Randomized controlled trial · GLP-1 receptor agonist · Type 2 diabetes · weight loss · Body weight reduction · Placebo-controlled trial · Cardiometabolic disease · Kansas City Cardiomyopathy Questionnaire · exercise function · 6-minute walk distance · C-reactive protein · Natriuretic peptides · Cardiovascular events · Obesity · Diastolic dysfunction · Quality of life · Symptom burden · Weight management · Cardiometabolic risk factors · Heart failure phenotyping · Anti-obesity medication · Diabetes-related comorbidities · Secondary analysis · Patient-reported outcomes
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Heart Failure Treatment and Management Papers, Class of 2026. https://pri.pepkio.com/top-papers/heart-failure-treatment-and-management/2026. Accessed 2026-07-13. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459